Abstract
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Clinical Trials as Topic
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Integrase / genetics
-
HIV Integrase / metabolism
-
HIV Integrase Inhibitors / therapeutic use*
-
HIV-1 / drug effects*
-
HIV-1 / enzymology*
-
HIV-1 / physiology
-
Heterocyclic Compounds, 3-Ring / therapeutic use*
-
Humans
-
Oxazines
-
Piperazines
-
Pyridones
-
Pyrrolidinones / therapeutic use
-
Quinolones / therapeutic use
-
Raltegravir Potassium
Substances
-
HIV Integrase Inhibitors
-
Heterocyclic Compounds, 3-Ring
-
Oxazines
-
Piperazines
-
Pyridones
-
Pyrrolidinones
-
Quinolones
-
Raltegravir Potassium
-
elvitegravir
-
dolutegravir
-
HIV Integrase